1st Quarter - Report

BALLARD PARTNERS for FERRING PHARMACEUTICALS, INC.

Firm
Client
Income
$110,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Tariff (miscellaneous tariff bills) TAR

Advocacy regarding IVF access and tariffs.

Foreign entity interest: Ferring Holding SA, as a parent company of Ferring Pharmaceuticals, Inc., identified on the LD-1 report, has indirect interest in the issues identified in this report.

LobbyistCovered position, as disclosed
ALISON ANWAY LA to Senator Pat Roberts 2006-2010
BRIAN BALLARD —
HUNTER MORGEN New Policy Advisor, Office of Policy Planning, U.S. State Dept. (2017); Deputy Director, Office of Trade & Manufacturing Policy, WH (2017-2018); Special Assistant to the President, Office of the Senior Advisor for Policy, WH (2018-2020)

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.